Briggs Morrison, Crossbow Therapeutics CEO
July 11, 2023 07:30 AM EDT
Financing
Startups

Ex­clu­sive: Brig­gs Mor­rison's Cross­bow Ther­a­peu­tics nabs $80M from MPM, Pfiz­er Ven­tures, Lil­ly in hunt for bet­ter can­cer drugs

Kyle LaHucik

Senior Reporter

Brig­gs Mor­ri­son is ready to take on can­cer with a new ar­se­nal of an­ti­bod­ies that his biotech hopes will be more pre­cise and tu­mor-killing than …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

A service from the Financial Times